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Abstract
Background: Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs
of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases.
Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objective response rate and long median
survival after treatment. However, complete remission is almost never achieved. The liver is the most commonly
affected organ in metastatic disease and is the most incriminating factor for patient survival. Additional treatment
of liver disease after PRRT may improve outcome in NET patients. Radioembolization is an established therapy for
liver metastasis. To investigate this hypothesis, a phase 2 study was initiated to assess effectiveness and toxicity of
holmium-166 radioembolization (166Ho-RE) after PRRT with lutetium-177 (177Lu)-DOTATATE.
Methods: The HEPAR PLUS trial (“Holmium Embolization Particles for Arterial Radiotherapy Plus 177Lu-DOTATATE in
Salvage NET patients”) is a single centre, interventional, non-randomized, non-comparative, open label study. In this
phase 2 study 30–48 patients with > 3 measurable liver metastases according to RECIST 1.1 will receive additional
166Ho-RE within 20 weeks after the 4th and last cycle of PRRT with 7.4 GBq 177Lu-DOTATATE. Primary objectives are to
assess tumour response, complete and partial response according to RECIST 1.1, and toxicity, based on CTCAE v4.03,
3 months after 166Ho-RE. Secondary endpoints include biochemical response, quality of life, biodistribution and
dosimetry.
Discussion: This is the first prospective study to combine PRRT with 177Lu-DOTATATE and additional 166Ho-RE in
metastatic NET. A radiation boost on intrahepatic disease using 166Ho-RE may lead to an improved response rate
without significant additional side-effects.
Trial registration: Clinicaltrials.gov NCT02067988, 13 February 2014. Protocol version: 6, 30 november 2016.
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Background
In accordance with the most recent WHO/ENETS criteria,
grade 1 and 2 neuroendocrine tumours (G1-/G2NET) are
regarded as well- to moderately-differentiated tumours and
grade 3 NET (G3NET) as poorly-differentiated NET or
neuroendocrine carcinomas (NEC) [1, 2]. At diagnosis, 21%
of all G1NET, 30% of all G2NET and 50% of all G3NET
have distant metastases, of which the liver is most com-
monly affected [3, 4]. A correlation between the organ of
origin and the likelihood of metastasis exists. For example,
rectal NET has a slim chance of distant metastasis (5%)
compared with pancreatic or colonic NET (respectively
64% and 53–86%) [3, 5]. Considering these numbers, many
patients will be ineligible for curative treatment, which
currently only includes surgical resection of the primary
tumour.
Most G1-/G2NET have membrane receptors for
somatostatin, allowing for targeted therapies, of which
somatostatin-analogs are the most commonly used (e.g.
octreotide). Treatment with somatostatin-analogs, che-
motherapeutics and kinase inhibitors show only limited
objective response rates in G1-/G2NET [6–12]. In
addition, systemic therapies give rise to systemic side
effects. In the last decade, the treatment of G1-/G2NET
with peptide receptor radionuclide therapies (PRRT) has
increased. High objective imaging response rates (CR +
PR 29–58%) [13–17], clinical and biological response
rates and a long median survival (95–128 months after
diagnosis, 46 months after treatment) [13, 14] can be
achieved after PRRT (Fig. 1).
All studies include high percentages of patients with
liver metastases and show a dismal prognosis with in-
creasing liver involvement (Table 1). As surgical resection
techniques develop, some forms of hepatic involvement
can be treated surgically. However, as three different pat-
terns of hepatic metastases are described in NET, patients
with the most common ‘diffuse pattern’ are not eligible for
surgical resection (Table 2) [4]. Besides, most systemic
therapies have a limited objective response rate. This
indicates a need for improved treatment of extensive liver
disease. In accordance with the ENETS guideline pub-
lished in 2012, the treatment of choice in patients with
NET liver metastases with a ‘diffuse’ or unresectable ‘com-
plex pattern’, consists of systemic treatment followed by
liver directed treatment [4]. Hepatic radioembolization
(RE) is one of the liver directed treatments and it is an
established minimal invasive treatment of patients with
liver malignancies. RE has been demonstrated to be effect-
ive and well tolerated in primary, as well as secondary liver
malignancies. A recent meta-analysis by Devcic et al.
showed an average objective response rate (CR + PR) of
50% and an average disease control rate of 86% in a het-
erogeneous group of NET treated with RE [18]. 166Ho-RE
is quite similar to 90Y-RE, but its distinct advantages will be
discussed later on. Figure 2 shows an example of 166Ho-RE
in a NET patient.
Fig. 1 Example of 177Lu-DOTATATE in NET. Upper row: planar whole body 111In-pentetreotide scintigraphy. Lower row: venous phased CT of the
liver. On the left baseline imaging and on the right imaging after 177Lu-DOTATATE treatment
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In the current clinical setting, RE is used for liver
dominant or liver isolated disease, often in a salvage setting.
In this study, it is hypothesized that improved outcome can
be obtained by escalating the treatment of liver metastases,
the most significant prognostic factor for NET patients,
additional to treatment of all extrahepatic disease in G1-/
G2NET patients, by combining systemic PRRT with RE. In
the presented study, patients with metastasized NET will
receive PRRT in 4 cycles of 7.4 GBq with 177Lu-DOTATA
TE, followed by 166Ho-RE in the University Medical Centre
Utrecht, the Netherlands, using 166Ho-microspheres. The
following paragraphs will address the details of the study.
Methods
Study design
The HEPAR PLUS study is a single centre, interventional,
non-randomized, non-comparative, open label study. In
this phase 2 study all patients will receive additional
166Ho-RE after 177Lu-DOTATATE. Overall, 30–48 pa-
tients with metastasized NET will be investigated for effi-
cacy and toxicity.
Subjects
Patients with NET and liver metastasis, who completed
4 cycles of 7.4 GBq 177Lu-DOTATATE, will receive add-
itional 166Ho-RE within 20 weeks of the last/fourth cycle
of 177Lu-DOTATATE. At time of recruitment, all included
patients have no need for conventional treatment options
like surgery or chemotherapy. In the Netherlands,
177Lu-DOTATATE is often a first- or second-line treat-
ment. Previous treatments prior to 177Lu-DOTATATE
were no exclusion criterium. Detailed inclusion and exclu-
sion criteria are listed in Table 3.
Time schedule
Recruitment will take place between Augustus 2014
and January 2019. First participant was enrolled in
November 2014.
Medical device
166Ho-microspheres are produced by incorporating
non-radioactive 165Ho and its acetylacetonate complex
(165HoAcAc) in a poly(L-lactic acid) matrix to form
microspheres with an average diameter of 30 μm. By
neutron-activation in a nuclear facility, the prescribed
amount of radioactive 166Ho-microspheres are produced
[19, 20]. The radionuclide 166Ho has a half-life of 26.8 h,
is a beta-emitter (Εβmax = 1.85 MeV) and a gamma emit-
ter (Εγ = 81 keV). Due to their additional photon emit-
ting properties, 166Ho-microspheres can be visualized
and quantified using SPECT imaging [21, 22].
Recruitment
All patients have previously been treated with four cycles
of 177Lu-DOTATATE. After the fourth cycle patients are
eligible for study inclusion. The study physician (AJATB)
Table 1 Liver involvement as a poor prognostic factor in different therapeutic studies
Author Treatment N Liver involvement Median survival (months) 5-year survival p values
Chamberlain (2000) [46] Surgical resection 85 0–25% – 90%
25–50% – 83%
50–75% 47 80%
> 75% 24 –
Yao (2001) [47] Surgical resection 16 ≤4 liver metastases 46 – < 0.05
> 4 liver metastases 20 –
Gupta (2005) [48] TAE
or
TACE
123 0–25% 86 –
25–50% 30 – < 0.10
50–75% 39 – < 0.17
> 75% 20 – < 0.05
Kwekkeboom (2008) [14] PRRT 310 None > 48 –
Moderate > 48 –
Extensive 25 – < 0.01
Legend: TAE transarterial (bland) embolization, TACE transarterial chemoembolization, PRRT peptide receptor radionuclide therapy
Table 2 NET Liver involvement patterns [4]
Involvement Incidence
Simple pattern One lobe or two adjacent lobes 20–25%
Complex pattern Primarily one lobe and smaller satellites contralaterally 10–15%
Diffuse pattern Multifocal disease 60–70%
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and principal investigator (MGEHL) inform all patients;
thereafter informed consent will be obtained. On the in-
formed consent form, participants can indicate whether
they wish to receive a summary of the trial results, once
the trial is completed.
Statistical analysis
This single arm open label study will have a sequential
design. Stopping boundaries are determined such that an
overall one-side alpha of at the most 0.05 is maintained in
case the true tumour response is 20%. Early termination
at a response interim analysis (after 30, 36 or 42 patients)
is determined by pre-defined boundaries on the number
of partial and complete responses according to RECIST
1.1 (Table 4). A superiority or futility boundary may be
reached or crossed before 30 patients are reached, but the
study will continue to at least 30 patients to allow estima-
tion of the key secondary endpoints. The sequential design
with boundaries as given in Table 4 will have a power of
90% to reach a positive tumour response decision in case
Fig. 2 Example of 166Ho-radioembolization in NET. A patient with a grade 2 small intestinal NET according to the WHO-criteria, treated in the
prior HEPAR 2 trial. On the left, the 18FDG-PET and venous phased CT at baseline. In the middle, the imaging studies 3 months after 166Ho-RE
with partial metabolic 18FDG-PET response and some tumour reduction on CT. On the right, follow-up imaging studies 6 months after 166Ho-RE
with significant partial metabolic response and significant tumour reduction on CT
Table 3 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patient must have given a written informed consent Brain metastases or spinal cord compression, unless irradiated > 4 weeks prior to 166Ho-RE
and stable for at least 1 week without steroids
≥ 18 years of age Serum bilirubin > 1.5 x upper limit of normal
Confirmed histological diagnosis NET Glomerular filtration rate < 35 ml/min
Prior treatment with 4 cycles of 7.4 GBq 177Lu-DOTATATE
within 20 weeks before 166Ho-RE
Alkaline phosphatase, alanine aminotransferase or aspartate aminotransferase > 5 x upper
limit of normal
Life expectancy > 12 weeks Leucocytes < 2.0 × 109/l and/or platelet count < 50 × 109/l
WHO performance score 0–2 Significant cardiac event within 3 months of inclusion
≥ 3 measurable liver lesions according to RECIST 1.1 Patients suffering from diseases with an increased chance of liver toxicity
Negative pregnancy test for women of childbearing
potential
Patients declared incompetent or suffering from psychic disorders making comprehensive
judgment impossible
No nursing activities for women of childbearing
potential
Severe bile duct abnormalities: papillotomy, cholecystectomy, biliary stents and bilidigestive
anastomosis are allowed
Acceptable method of contraception Body weight > 150 kg
Severe contrast allergy
Liver tumour involvement > 70% on CT
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the true target lesions tumour response is 40%. The exact
overall one-sided type I error is 4.5%.
Interim analysis of toxicity with descriptive statistics (N,
mean, median, etc.) will be performed for every 3 patients.
All analysis will be performed in the Full Analysis Set
(FAS), including all patients who received at least the
scout dose procedure (see below). The Per Protocol Set
(PPS) will include all patients who complied with the
protocol up to at least 3 months. PPS analyses will be used
for the primary endpoint. For the assessment of the pri-
mary objective at least 30 patients should have a 3 months
follow-up CT-scan. If patients do not reach the 3 months
follow-up CT-scan or receive a new treatment prior to the
evaluation moment, a new patient will be included for the
PPS analysis.
Monitoring
All safety interim analyses will be presented to our Inde-
pendent Data Monitoring Commission (IDMC), consisting
of one interventional radiologist, one nuclear medicine
physician, one gastroenterologist and one biostatistician.
All IDMC members are not involved in the trial and have
no conflicting interests. Additionally, safety analysis will be
performed every 3 months during the recruitment of the
first 30 patients, after patient 36, patient 42 and patient 48,
and evaluated by the IDMC.
Severe adverse (device) events will be reported to the
Ethics Committee of the University Medical Center
Utrecht and IDMC within 8 days. In accordance with
Dutch regulations on research with medical devices, a
summary of all severe adverse (device) events will be
reported to the Dutch Health Care Inspectorate (in
Dutch: Inspectie GezondheidsZorg en Jeugd in opricht-
ing; IGJ) every 3 months.
Data management
All patient data collected in this trial, will be coded. All
coded data will be entered in to an, in-house developed,
electronic case report form (e-CRF) in a secure digital
environment. All collected data is monitored and validated
by an independent, external data monitor approximately
every 3–4 months. In accordance with Dutch regulations,
all collected data will be stored for a duration of 15 years.
Trial data is only accessible to the study physician, princi-
pal investigator and external data monitor.
Ethical considerations
The study protocol has been approved by the Ethics
Committee and the institutional radiation protection
committee of the University Medical Centre Utrecht, the
Netherland. This study will be performed in accordance
with the Declaration of Helsinki (current version October
2013), the Medical Research Involving Human Patients
Act (WMO, the Netherlands) and the requirements of
International Conference on Harmonization (Good Clin-
ical Practice). In accordance to regulations, all future
protocol amendments need Ethics Committee approval.
Unexpected harm to the participant during the trial, is
covered by the institutions’ insurance for clinical trials.
Funding
This phase 2 study is funded by the Department of Radi-
ology and Nuclear Medicine of the University Medical
Center Utrecht. No external funding received.
Treatment
Screening
After obtaining informed consent, all study proceedings will
occur in the University Medical Center Utrecht, Utrecht,
The Netherlands. A screening visit will take place at the
outpatient clinic prior to the first angiography. The study
physician and principal investigator will check in- and
exclusion criteria, perform a physical examination (includ-
ing blood pressure, temperature and heart rate) and assess
the WHO performance status of the patient. All patients
are asked to fill out the European Organization for
Research and Treatment of Cancer (EORTC) QLQ-C30
and QLQ-GINET21 questionnaires. Additional tests in-
clude relevant laboratory testing (haematology, coagulation
profile and serum chemistry) including a tumour marker
(when present/measurable in the patient), electrocardio-
gram (ECG) and a contrast-enhanced CT. All contrast
enhanced CT’s will be assessed by RECIST 1.1 criteria [23].
Angiography
Patients are admitted for 3 days (2 nights) starting the day
prior to the angiography. After physical examination and
relevant laboratory testing, patients are pre-hydrated to pre-
vent kidney damage, and started on proton pump inhibitors
for 6 weeks (pantoprazole once a day 40 mg). Premedica-
tion 1 h prior to the angiography consists of one dose of
corticosteroids, antihistamines and anti-emetics (respect-
ively dexamethasone 10 mg, clemastine 1 mg and ondanse-
tron 8 mg), at the same time a tranquilizer is offered to the
patient (oxazepam 10 mg). If the patient is familiar with a
mild to moderate contrast allergy, additional corticosteroids
and antihistamines will be given prior to the angiography
according with national guidelines of the Central Accom-
paniment Institution (CBO in Dutch) [24].
Table 4 Stopping boundaries for early termination at interim
analysis
Analysis Sample Size Lower boundary Upper boundary
1 30 5 11
2 36 6 13
3 42 7 14
4 48 15 16
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A skilled and trained interventional radiologist will
perform all angiographies of the upper abdominal vessels.
A catheter is introduced via one of the femoral arteries by
the Seldinger technique. After identifying all arteries sup-
plying the liver, additional branches of these arteries that
supply other organs than the liver are coiled, if needed.
This usually involves the gastroduodenal artery (GDA)
and right gastric artery (RGA).
Scout dose
Once successful identification of the supplying arteries
and occlusion of additional branches has been performed,
a scout dose of 250 MBq 166Ho-microspheres will be ad-
ministered [20, 25]. Due to the photon emission of 166Ho,
distribution of the microspheres, lung shunting and extra-
hepatic depositions can all be assessed using SPECT/CT.
Planar imaging and SPECT/CT will be performed follow-
ing the angiography and evaluated qualitatively as well as
quantitatively. Extrahepatic deposition of activity is a
contra-indication for treatment. Lung shunting will be
assessed by planar imaging and SPECT/CT and should
not exceed the maximum tolerable lung absorbed dose
(i.e. 30 Gy).
Treatment
If the pre-treatment assessment is successful, patients
return to the angiography suite for the treatment
angiography combined with the 166Ho-RE. This will
take place on the same day as the pre-treatment angi-
ography and scout dose procedure (see Fig. 3). Based
on the results of the dose escalation study (i.e.
HEPAR I trial), a whole liver absorbed dose of 60 Gy
was determined to be safe. A whole liver absorbed
dose of 60 Gy leads to the following equation for
activity calculation:
A166Ho MBqð Þ ¼ 3781 MBq  GyJ
 
 liver weight kgð Þ
As mentioned above, additional information derived
from the scout dose SPECT/CT can change treatment
planning, either performing a one session whole liver
treatment or two session sequential whole liver treatment.
A significant lung shunt dose (> 30 Gy) will lead to a
reduction in treatment activity.
Radiation exposure rate
The radiation exposure rate of the patient will be measured
from 1-m distance at t = 0 h and t = 24 h after the
166Ho-RE.
Fig. 3 Study protocol depicting the time line and study proceedings between inclusion and hospital discharge
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Follow-up
Follow-up visits During 12 months after treatment,
patients are followed at the outpatient clinic. The visits will
take place after 3 weeks, 6 weeks, 3 months, 6 months,
9 months and 12 months (closing visit). During these visits
patients will undergo a physical examination, laboratory
testing, WHO performance status assessment and will be
monitored for (serious) adverse (device) events. Prior to the
3 weeks, 6 weeks and 3 months visits, patients are asked to
fill out the EORTC questionnaires (QLQ-C30 and
QLQ-GI.NET21). Prior to the 3, 6, 9 and 12 months visits,
a CT will be performed for response assessment according
to the RECIST 1.1 criteria.
Primary objectives Two distinct objectives are the focus
of our study. Tumour response on CT at 3 months of
follow-up will be the first primary objective. This is
defined as complete response (CR = disappearance of all
lesions) or partial response (PR = ≥30% decrease in the
sum of the longest diameters of the target lesions, com-
pared to baseline measurements). The second primary
objective is to establish the safety and toxicity profile of
treatment with 166Ho-RE as an additional treatment after
177Lu-DOTATATE, using the Common Terminology
Criteria for Adverse Events (CTCAE version 4.03) [26].
Secondary objectives Three secondary objectives have
been defined. Anti-tumour effect will be assessed by
relevant tumour markers (when available), expressed as
a percentage of the pre-treatment values. Furthermore,
Quality of Life (QoL) will be assessed using the EORTC
questionnaires (QLQ-C30 and QLQ-GI.NET21) during
the first 3 months after treatment. The impact of treat-
ment on QoL will be compared to tumour response and
other parameters.
Additionally, biodistribution and dosimetry will be
evaluated using a dual isotope fusion SPECT/CT proto-
col. After the standard scout dose SPECT/CT and treat-
ment dose SPECT/CT (i.e. 166Ho-SPECT), 50 MBq of
99mTc-phytacis (CIS bio, France) will be administered.
Subsequently a dual-isotope SPECT/CT will be acquired,
simultaneously providing a 166Ho-SPECT for assessment
of microsphere distribution and a 99mTc-phytacis SPECT
for the assessment of truly functional liver parenchyma.
Safety profile The phase 1 study on 166Ho-RE (HEPAR I
trial) [20] and its subsequent phase 2 study (HEPAR 2
trial) [27], demonstrated similar treatment-related effects
as the current commercially available 90Y-microspheres.
Common adverse events up to grade 1 or 2 of the CTCAE
v4.03 included: fever, nausea, vomiting, abdominal dis-
comfort, and fatigue, often called the post-embolization
syndrome. These complaints were generally self-limiting
within 4–6 weeks. More serious adverse events of RE in
general were rare (< 1%) and included RE-induced liver
disease (REILD) [28] and inadvertent extrahepatic distri-
bution of activity [29].
Escape medication The protocol ensures all patients are
pre- and post-hydrated in order to minimize the chance of
renal insufficiency caused by the vascular contrast agent,
jodixanol (Visipaque®). After 166Ho-RE standard escape
medication includes paracetamol up to 4000 mg / day and
ondansetron up to 24 mg, as respectively oral analgesic
and intravenous anti-emetic. If persisting nausea occurs,
additional metoclopramide up to 120 mg / day will be
used. In case of diarrhoea, patients will receive loperamide
up to 16 mg / day. In this specific patient group, some pa-
tients might experience excessive release of NET-related
hormones that could cause a ‘carcinoid syndrome’ or
‘carcinoid crisis’. These complaints can be prevented (to
some extent) with octreotide intravenously, steroids and
hydration.
Withdrawal of individual patients Patients may be
withdrawn from the study if a serious adverse event
occurs.
Patients will be withdrawn from the study if 1) the in-
vestigator considers it in the best interest of the patient
that he/she be withdrawn (e.g. progressive disease), 2)
the patient withdraws consent or 3) the patient is unable
to comply with the protocol procedures.
Discussion
Liver metastases significantly limit patient survival
(Table 1). In the current study, the beneficial effect of
additional 166Ho-RE within 12 weeks after systemic
177Lu-DOTATATE will be investigated. Combining these
treatments may lead to an improved response rate for liver
metastases, with acceptable and suppressible side effects,
which may eventually lead to prolonged survival. Although
the latter question is not an objective of the current phase
2 study, if significant efficacy and limited toxicity are
shown, a subsequent phase 3 study might be initiated.
To date, Ezziddin et al. published the only report
describing RE with 90Y-microspheres after PRRT with
177Lu-DOTATATE in a retrospective study [30]. They
described a population of 23 patients in which RE was
performed in a salvage setting. Patients had progressive
or functionally uncontrolled disease after PRRT. Three
months after RE, 30% had PR and 61% had stable disease
without any serious toxicity, comparable with other re-
ports on 90Y-microspheres in NET patients. The authors
concluded that salvage RE after PRRT shows a toxicity
profile similar to RE alone, despite the high cumulative
activity administrated. Less than 15% experienced a
CTCAE grade 3 toxicity (abdominal pain, fatigue, fever,
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nausea and vomiting) and one patient developed a
gastroduodenal ulcer. The interval between PRRT and
RE was not mentioned, but patients were only referred
for RE in case they had progressive disease (i.e. salvage
setting). In their study, a cumulative liver dose of 2–
12 Gy was described after PRRT. Due to the hypervascu-
lar nature of NET, the absorbed dose on healthy liver
parenchyma due to RE is (far) below the presumed tox-
icity limit of healthy liver tissue (i.e. 70 Gy; and 50 Gy in
cirrhotic livers with 90Y resin microspheres) [31]. Thus,
in theory, combining RE and PRRT can be safe. None-
theless, concerns arise when implementing RE shortly
after PRRT, due to the cumulative radiation dose and
the short interval, potentially provoking REILD [28]. On
the other hand in a recent case report, Filippi et al.
described their treatment combination a patient with
one hepatic metastasis, mesenteric metastasis and
several bone metastases, diagnosed on a 68Ga-DOTATA
TE-PET/CT [32]. The hepatic metastasis was down-
staged with a lobar RE procedure, followed by 4 cycles
of PRRT to treat extrahepatic lesions (a mesenteric
metastasis and several bone metastases). Restaging after
3 months with a 68Ga-DOTATATE-PET/CT showed a
nearly complete remission of the extrahepatic metastases
and an incomplete remission of the hepatic metastasis,
thus another additional lobar RE procedure was per-
formed to treat the hepatic lesion, with success [32].
They reported no significant adverse events of the com-
bined treatments, complete symptomatic control and a
survival of 42 months [32]. Additionally, they reported
an absorbed dose on healthy liver parenchyma after the
RE procedures of just 18 Gy and 20 Gy [32]. An example
that the combination of RE and PRRT with short inter-
vals can be safe.
In contrast to other studies, 99mTc-macroaggregated
albumin (99mTc-MAA) will not be used as a scout dose for
treatment planning. Instead, a small number of 166Ho-mi-
crospheres will be used as a scout dose (approximately
250 MBq). This may overcome known limitations of
99mTc-MAA: 1) differences in flow dynamics caused by
the randomly shaped 99mTc-MAA particles (90% between
10 and 90 μm) versus the spherically shaped 166Ho-micro-
spheres (30 ± 5 μm), 2) differences in scanning protocols
of pre- and post-procedural imaging (i.e. 99mTc-SPECT vs
90Y-PET versus 166Ho SPECT for both procedures), 3)
employing a similar injection technique during both angi-
ographies (i.e. bolus 99mTc-MAA versus intermittent injec-
tion of 166Ho microspheres), and 4) overestimation of the
lung shunt using 99mTc-MAA.
As shown by Elschot et al., in patients treated with
166Ho-RE, using 99mTc-MAA as well as 166Ho-micro-
spheres as pre-treatment imaging scout dose, 166Ho-S-
PECT/CT was the most accurate in predicting the lung
absorbed dose after 166Ho-RE [33]. On 166Ho-SPECT/
CT a median lung shunt dose of 0.02 Gy was calculated.
This was significantly overestimated in lung shunt dose
calculations based on 99mTc-MAA planar scintigraphy
(5.5 Gy), 166Ho planar scintigraphy (10.4 Gy) and
99mTc-MAA SPECT/CT (2.5 Gy). An example of severe
overestimation by 99mTc-MAA compared to 166Ho-mi-
crosperes is shown in Fig. 4. In the present study biodis-
tribution / extrahepatic deposition assessment and lung
Fig. 4 Example of lung shunt fraction overestimation by 99mTc-MAA. A patient with multiple liver metastases of a cholangiocarcinoma treated
in the prior HEPAR 2 trial. Note the (visual) significant overestimation of 99mTc-MAA on planar imaging compared to the 166Ho-scout dose and
166Ho-treatment dose. Quantification of the lung shunt fraction on planar and SPECT/CT imaging confirmed the visual assessment: a 99mTc-planar
= 13.4%, d 99mTc-SPECT = 6%, all 166Ho imaging modalities (b, c, e and f) with the scout dose and with the treatment dose showed a lung shunt
fraction of < 1%
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shunt dose calculation will solely be evaluated by
166Ho-SPECT/CT.
The safety of administrating 250 MBq of beta-emitting
166Ho-microspheres as a scout dose has been studied by
Prince et al. [25] They predicted the amount of extrahepatic
activity and radiation absorbed dose, using 99mTc-MAA
SPECT/CT of 160 patients prior to 90Y-RE. Based on a
prior study by Kao et al., they defined a dose exceeding
49 Gy as clinically significant [25, 34, 35]. Simulating the
use of 250 MBq 166Ho-microspheres as a scout dose, only
1.3% of the patients had an extrahepatic deposition that
could potentially be harmful (i.e. exceeded a mean dose of
49 Gy) [25]. Additionally, C-arm CT’s will be acquired at
each injection position, prior to scout dose administration,
to minimize the chance of extrahepatic depositions and
partial tumour coverage, and to avoid extra angiography
procedures [36, 37].
As mentioned in the ‘secondary objectives’ section, the
application of the dual isotope SPECT/CT protocol will
enable us to derive all relevant dosimetric parameters for
treatment dose calculation. 99mTc-phytacis, like other radio-
colloids, is extracted from the blood pool by the reticuloen-
dothelial cells of the liver [38]. Solely the functional liver
parenchyma is depicted, due to absence of reticuloendothe-
lial cells in tumours. Validation of this dual-isotope protocol
will be performed in a side-study. Previous studies by Lam
et al. have shown the prognostic value of the combination
of 99mTc-MAA and 99mTc-sulphur colloid imaging, showing
a tumour dose-response correlation and healthy liver
dose-toxicity correlation [39, 40].
As an additional advantage, holmium is one of the 14
lanthanide elements, making 166Ho-microspheres
MRI-compatible for treatment imaging. In short, using
estimated R2* value changes from multi-gradient echo
data, the holmium concentration per voxel could be
determined [41, 42]. Conversion into units of activity
enables dosimetric calculations. A prior study by Smits
et al. has shown its feasibility in clinical practice and its
comparability to SPECT-based dosimetry [21]. Using a
similar MR-sequence, real-time imaging of the
166Ho-microspheres during administration may become
a future application [43]. However, the use of MRI is
beyond the scope of this study, to minimize the study
impact for patients.
In contrast to RE, PRRT’s main limitation is absorbed
kidney dose. To reduce the dose, the most important
preparatory measure is intravenous amino acid infusion
prior, during and after 177Lu-DOTATATE administration.
To overcome the disadvantage of the unavoidable kidney
dose, intra-arterial administration of 177Lu-DOTATATE in
patients with liver only disease could be a future applica-
tion [44]. Several studies show a decreased absorbed
kidney dose and an increased uptake in the liver metasta-
ses in most patients after intra-arterial administration. In a
study by Pool et al., kidney absorbed dose decreased by
13% in addition to a 2.9-fold increase in liver metastases
uptake [45]. In theory, a combination of intra-arterial
PRRT and RE could be superior in patients with liver only
disease.
Limitations of the study protocol are the small study
cohort, non-comparative design, single center design
and relatively short clinical follow-up for NET patients.
In conclusion, combining PRRT and RE could lead to
improved treatment response and additional survival
benefit: PRRT can be used to treat intra- and extrahepatic
disease, whereas RE leads to an additional radiation boost
on intrahepatic disease, the most incriminating factor in
NET-patients’ survival. Based on this hypothesis, the
HEPAR PLUS trial will include all patients treated with
177Lu-DOTATATE with significant intrahepatic disease.
Recruitment status
Ongoing: Currently recruiting patients.
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